Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary

Status Completed

Clinical Trial Summary

The goal of the current study is to determine whether Foundation Medicine's next generation sequencing assay, called FoundationOne, will provide information that allows physicians to make treatment decisions using targeted therapies in clinical trials or FDA approved therapies, including "off-label" agents, that result in superior OS compared to historical outcomes for standard CUP therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adenocarcinoma
Carcinoma
Carcinoma, Squamous Cell
CUP
Metastatic Disease
Neoplasm Metastasis
Neoplasms, Unknown Primary
Poorly Differentiated Adenocarcinoma
Poorly Differentiated Carcinoma
Squamous Carcinoma Poorly Differentiated

Clinical Trial Details

NCT number	NCT02628379
Study type	Observational
Source	Foundation Medicine
Contact
Status	Completed
Phase
Start date	May 2015
Completion date	March 2017

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01450683` - Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy	Phase 2
Terminated	`NCT04116164` - Safety and Targeting of Anti-hk2 Antibody in mCRPC	Early Phase 1
Completed	`NCT04595032` - MAnagement of METastatic Disease In Campania (MAMETIC)
Terminated	`NCT01020305` - Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer	Phase 1/Phase 2
Withdrawn	`NCT02496832` - A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo	N/A
Completed	`NCT01763970` - Stereotactic Radiation Therapy for Pediatric Sarcomas	N/A
Completed	`NCT01703910` - Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic	Phase 2
Completed	`NCT00609401` - Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)	Phase 2
Completed	`NCT00480389` - Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal	Phase 2
Recruiting	`NCT03632005` - Negative Pressure Wound Therapy vs. Sterile Dressing for Patients Undergoing Thoracolumbar Spine Surgery	N/A
Recruiting	`NCT04492735` - The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
Terminated	`NCT02175654` - Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab	Phase 2
Not yet recruiting	`NCT01861938` - Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients	Phase 2/Phase 3
Completed	`NCT01875380` - Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer	Phase 2
Terminated	`NCT00532454` - Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen	Phase 2
Terminated	`NCT02795819` - Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer	Phase 1
Recruiting	`NCT05188911` - Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
Completed	`NCT03823989` - Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients	Phase 1
Terminated	`NCT01904916` - CPCT-05 Biopsy Protocol Patient Selection	N/A
Terminated	`NCT01484860` - Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy	Phase 2